Germany Pharmaceuticals Market Size Worth $65.9 Billion By 2027 | Global and Regional Forecast | Grand View Research, Inc.

The Germany pharmaceuticals market size is expected to reach USD 65.9 billion by 2027, expanding at a CAGR of 6.0%, according to a new report by Grand View Research, Inc. Factors such as the rising prevalence of acute and chronic diseases and increasing R&D expenditure by pharmaceutical companies are expected to drive the market.
Furthermore, rising clinical trials and
approval of novel immune-suppressive therapies are anticipated to propel market
growth. For instance, in June 2020, Sandoz International GmbH launched
Dailiport capsules (generic tacrolimus) in Germany and other European
countries. Dailiport capsules are indicated for adult kidney and liver
transplant patients.
In addition, the export of pharmaceutical
products by pharmaceutical companies in Germany to various countries is
expected to fuel market growth. For instance, according to Germany Trade and
Invest, in China, 22.0% of imported pharmaceutical products are from German
companies.
Key players entering into strategic
initiatives such as partnership, licensing, acquisition, and collaboration to
expand and strengthen their regional presence is expected to boost the market
growth. For instance, in November 2019, Bristol-Myers Squibb Company acquired
Celgene Corporation. This acquisition was aimed at helping the company expand
its oncology portfolio worldwide and develop innovative medicines.
In addition, rising funds by organizations
for the development of pipeline drugs are anticipated to accelerate market
growth. For instance, in January 2019, Atriva Therapeutics GmbH closed its
series A financing led by Meneldor and High-Tech Gründerfonds GmbH (HTGF) for
its lead drug candidate ATR-002. This drug candidate is developed against
influenza infection and other respiratory infections.
Various other organizations, such as the
European Cancer Organisation (ECCO), European Cancer Patient Coalition (ECPC),
and European Organisation for Research and Treatment of Cancer (EORTC) provide
funds for cancer research programs and treatment plans.
Furthermore, increasing the availability of
generic drugs at a lower price is expected to boost the market growth. For
instance, in July 2019, Sandoz of Novartis AG launched a generic version of
gefitinib for locally advanced or metastatic NSCLC. The launch of the generic
version is estimated to increase the number of patients treated due to the
favorable cost of the drug.
Browse Full Report (Tables & Figures) @
https://www.grandviewresearch.com/industry-analysis/germany-pharmaceuticals-market
Contact
Us:
Grand View Research, Inc.
201 Spear Street 1100,
San Francisco, CA 94105
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Comments
Post a Comment